07 Oct 2026, 08:43 IST
Zydus Lifesciences Limited
Motilal Oswal Financial Services Ltd. (MOFSL) · POSITIVE
The note says Zydus, with MSN Laboratories, launched the first generic Adempas (Riociguat) in the US across all five strengths, and projects 23.5% YoY revenue growth with 23.2% EBITDA margin; CMP INR 1,160.
From MOStMarketOutlook07102026, written by Motilal Oswal Financial Services Ltd. (MOFSL) and hosted by Investment Guru India. Orivam summarised it; the view is Motilal Oswal Financial Services Ltd. (MOFSL)'s, not Orivam's.
Open the original PDF on Investment Guru India →Research PDFs are often removed by the firms that publish them. The summary above is kept so this page still means something if that happens.